FDA denies approval for Actavis hypertension treatment

By

Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan.

The company said it would review the U.S. Food and Drug Administration's complete response letter and decide on appropriate next steps.

The regulator issues a complete response letter when a new or generic treatment cannot be approved in its current form.

Actavis did not give any further details on the contents of the letter.

In a study, the drug combination was found more effective in reducing blood pressure in patients of hypertension, compared with independent doses of nebivolol and valsartan, Actavis said.

The company's shares closed at $254.20 on the New York Stock Exchange on Wednesday.

Tags
U.S., U.S. Food and Drug Administration
Join the Discussion
More News
Trump-Appointed Judge Orders Return Of Another Migrant Deported To El Salvador Claiming It Violates a Settlement

Detroit Uber Eats Driver Sent to El Salvador After Making a Wrong Turn While Delivering McDonald's

Joeylin

Teen Dead After Falling Through the Ceiling of After-School Facility While Exploring the Attic Unsupervised

Charles Read

Paralyzed Man Arrested Despite Ex-Girlfriend Saying He Fled Alleged Attack on Foot, Kicked in Her Door

Meteorologist Extortion_04242025_1

Virginia Weatherman Threatened to Release Sex Tape Recorded Without Victim's Knowledge: Police